Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity

References

• Burgess AW. EGFR family: structure physiology signalling and therapeutic targets. Growth Factors 2008; 26:263 - 74; http://dx.doi.org/10.1080/08977190802312844; PMID: 18800267
   PubMed Web of Science ®Google Scholar
• Engelman JA, Settleman J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev 2008; 18:73 - 9; http://dx.doi.org/10.1016/j.gde.2008.01.004; PMID: 18325754
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19:6550 - 65; http://dx.doi.org/10.1038/sj.onc.1204082; PMID: 11426640
   PubMed Web of Science ®Google Scholar
• Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19:183 - 232; http://dx.doi.org/10.1016/1040-8428(94)00144-I; PMID: 7612182
   PubMed Web of Science ®Google Scholar
• Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH Jr., Mendelsohn J. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993; 85:1327 - 33; http://dx.doi.org/10.1093/jnci/85.16.1327; PMID: 8340945
   PubMed Web of Science ®Google Scholar
• Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993; 53:4637 - 42; PMID: 8402640
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337 - 45; http://dx.doi.org/10.1056/NEJMoa033025; PMID: 15269313
   PubMed Web of Science ®Google Scholar
• Giusti RM, Shastri K, Pilaro AM, Fuchs C, Cordoba-Rodriguez R, Koti K, Rothmann M, Men AY, Zhao H, Hughes M, et al. U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Clin Cancer Res 2008; 14:1296 - 302; http://dx.doi.org/10.1158/1078-0432.CCR-07-1354; PMID: 18316547
   PubMed Web of Science ®Google Scholar
• Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn WD Jr., Morse D, Abraham S, Rahman A, Liang C, Lostritto R, et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004; 10:1212 - 8; http://dx.doi.org/10.1158/1078-0432.CCR-03-0564; PMID: 14977817
   PubMed Web of Science ®Google Scholar
• Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, et al, TRIBUTE Investigator Group. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23:5892 - 9; http://dx.doi.org/10.1200/JCO.2005.02.840; PMID: 16043829
   PubMed Web of Science ®Google Scholar
• Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355:2733 - 43; http://dx.doi.org/10.1056/NEJMoa064320; PMID: 17192538
   PubMed Web of Science ®Google Scholar
• Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25:3230 - 7; http://dx.doi.org/10.1200/JCO.2006.10.5437; PMID: 17664471
   PubMed Web of Science ®Google Scholar
• Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006; 12:7232 - 41; http://dx.doi.org/10.1158/1078-0432.CCR-06-0658; PMID: 17189394
   PubMed Web of Science ®Google Scholar
• Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007; 25:587 - 95; http://dx.doi.org/10.1200/JCO.2006.07.3585; PMID: 17290067
   PubMed Web of Science ®Google Scholar
• Azzoli CG, Baker S Jr., Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, et al, American Society of Clinical Oncology. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009; 27:6251 - 66; http://dx.doi.org/10.1200/JCO.2009.23.5622; PMID: 19917871
   PubMed Web of Science ®Google Scholar
• Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002; 62:200 - 7; PMID: 11782378
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039 - 43; http://dx.doi.org/10.1126/science.1141478; PMID: 17463250
   PubMed Web of Science ®Google Scholar
• Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, Gondi V, Hsu KT, Harari PM. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008; 27:3944 - 56; http://dx.doi.org/10.1038/onc.2008.19; PMID: 18297114
   PubMed Web of Science ®Google Scholar
• Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda M, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 2011; 3:99ra86; http://dx.doi.org/10.1126/scitranslmed.3002442; PMID: 21900593
   PubMed Web of Science ®Google Scholar
• Giles KM, Kalinowski FC, Candy PA, Epis MR, Zhang PM, Redfern AD, Stuart LM, Goodall GJ, Leedman PJ. Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib. Mol Cancer Ther 2013; 12:2541 - 58; http://dx.doi.org/10.1158/1535-7163.MCT-13-0170; PMID: 24026012
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626 - 34; http://dx.doi.org/10.1200/JCO.2007.14.7116; PMID: 18316791
   PubMed Web of Science ®Google Scholar
• Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007; 67:2643 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-06-4158; PMID: 17363584
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27:663 - 71; http://dx.doi.org/10.1200/JCO.2008.20.8397; PMID: 19114683
   PubMed Web of Science ®Google Scholar
• De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008; 19:508 - 15; http://dx.doi.org/10.1093/annonc/mdm496; PMID: 17998284
   PubMed Web of Science ®Google Scholar
• Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboüé R, Tuech JJ, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007; 96:1166 - 9; http://dx.doi.org/10.1038/sj.bjc.6603685; PMID: 17375050
   PubMed Web of Science ®Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757 - 65; http://dx.doi.org/10.1056/NEJMoa0804385; PMID: 18946061
   PubMed Web of Science ®Google Scholar
• Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66:3992 - 5; http://dx.doi.org/10.1158/0008-5472.CAN-06-0191; PMID: 16618717
   PubMed Web of Science ®Google Scholar
• Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27:2091 - 6; http://dx.doi.org/10.1200/JCO.2009.21.9170; PMID: 19188670
   PubMed Web of Science ®Google Scholar
• Van Cutsem EJ, Oliveira J, ESMO Guidelines Working Group. Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19:Suppl 2 ii33 - 4; PMID: 18456760
   PubMedGoogle Scholar
• Duffy MJ, O’Donovan N, Crown J. Use of molecular markers for predicting therapy response in cancer patients. Cancer Treat Rev 2011; 37:151 - 9; http://dx.doi.org/10.1016/j.ctrv.2010.07.004; PMID: 20685042
   PubMed Web of Science ®Google Scholar
• De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11:753 - 62; http://dx.doi.org/10.1016/S1470-2045(10)70130-3; PMID: 20619739
   PubMed Web of Science ®Google Scholar
• Hawkes E, Cunningham D. Relationship between colorectal cancer biomarkers and response to epidermal growth factor receptor monoclonal antibodies. J Clin Oncol 2010; 28:e529 - 31, author reply e532-3; http://dx.doi.org/10.1200/JCO.2010.29.5626; PMID: 20679615
   PubMedGoogle Scholar
• Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, Byun DS, Nasser S, Arango D, Shin J, Klampfer L, et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 2008; 68:1953 - 61; http://dx.doi.org/10.1158/0008-5472.CAN-07-5659; PMID: 18339877
   PubMed Web of Science ®Google Scholar
• Prenen H, De Schutter J, Jacobs B, De Roock W, Biesmans B, Claes B, Lambrechts D, Van Cutsem E, Tejpar S. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 2009; 15:3184 - 8; http://dx.doi.org/10.1158/1078-0432.CCR-08-2961; PMID: 19366826
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Molinari F, De Dosso S, Saletti P, Martini M, Cipani T, Marrapese G, Mazzucchelli L, et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 2009; 4:e7287; http://dx.doi.org/10.1371/journal.pone.0007287; PMID: 19806185
   PubMed Web of Science ®Google Scholar
• Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE Jr.. Stat3 as an oncogene. Cell 1999; 98:295 - 303; http://dx.doi.org/10.1016/S0092-8674(00)81959-5; PMID: 10458605
   PubMed Web of Science ®Google Scholar
• Zhong Z, Wen Z, Darnell JE Jr.. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994; 264:95 - 8; http://dx.doi.org/10.1126/science.8140422; PMID: 8140422
   PubMed Web of Science ®Google Scholar
• Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002; 8:945 - 54; PMID: 11948098
   PubMed Web of Science ®Google Scholar
• Sehgal PB. Paradigm shifts in the cell biology of STAT signaling. Semin Cell Dev Biol 2008; 19:329 - 40; http://dx.doi.org/10.1016/j.semcdb.2008.07.003; PMID: 18691663
   PubMed Web of Science ®Google Scholar
• Darnell JE. Validating Stat3 in cancer therapy. Nat Med 2005; 11:595 - 6; http://dx.doi.org/10.1038/nm0605-595; PMID: 15937466
   PubMed Web of Science ®Google Scholar
• Lin Q, Lai R, Chirieac LR, Li C, Thomazy VA, Grammatikakis I, Rassidakis GZ, Zhang W, Fujio Y, Kunisada K, et al. Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol 2005; 167:969 - 80; http://dx.doi.org/10.1016/S0002-9440(10)61187-X; PMID: 16192633
   PubMed Web of Science ®Google Scholar
• Dobi E, Monnien F, Kim S, Ivanaj A, N’Guyen T, Demarchi M, Adotevi O, Thierry-Vuillemin A, Jary M, Kantelip B, et al. Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer. Clin Colorectal Cancer 2013; 12:28 - 36; http://dx.doi.org/10.1016/j.clcc.2012.09.002; PMID: 23083634
   PubMed Web of Science ®Google Scholar
• Haura EB, Sommers E, Song L, Chiappori A, Becker A. A pilot study of preoperative gefitinib for early-stage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance. J Thorac Oncol 2010; 5:1806 - 14; http://dx.doi.org/10.1097/JTO.0b013e3181f38f70; PMID: 20881637
   PubMed Web of Science ®Google Scholar
• Bonner JA, Yang ES, Trummell HQ, Nowsheen S, Willey CD, Raisch KP. Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinoma. Radiother Oncol 2011; 99:339 - 43; http://dx.doi.org/10.1016/j.radonc.2011.05.070; PMID: 21704410
   PubMed Web of Science ®Google Scholar
• Kijima T, Niwa H, Steinman RA, Drenning SD, Gooding WE, Wentzel AL, Xi S, Grandis JR. STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ 2002; 13:355 - 62; PMID: 12193474
   PubMedGoogle Scholar
• Lo HW, Hsu SC, Ali-Seyed M, Gunduz M, Xia W, Wei Y, Bartholomeusz G, Shih JY, Hung MC. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 2005; 7:575 - 89; http://dx.doi.org/10.1016/j.ccr.2005.05.007; PMID: 15950906
   PubMed Web of Science ®Google Scholar
• Sen M, Joyce S, Panahandeh M, Li C, Thomas SM, Maxwell J, Wang L, Gooding WE, Johnson DE, Grandis JR. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Clin Cancer Res 2012; 18:4986 - 96; http://dx.doi.org/10.1158/1078-0432.CCR-12-0792; PMID: 22825581
   PubMed Web of Science ®Google Scholar
• Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, Paty PB, Rohle D, Vivanco I, Chmielecki J, et al. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci U S A 2009; 106:9435 - 40; http://dx.doi.org/10.1073/pnas.0900571106; PMID: 19478061
   PubMed Web of Science ®Google Scholar
• Skrzypczak M, Goryca K, Rubel T, Paziewska A, Mikula M, Jarosz D, Pachlewski J, Oledzki J, Ostrowski J. Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability. PLoS One 2010; 5:e13091; http://dx.doi.org/10.1371/annotation/8c585739-a354-4fc9-a7d0-d5ae26fa06ca; PMID: 20957034
   PubMedGoogle Scholar
• Zou TT, Selaru FM, Xu Y, Shustova V, Yin J, Mori Y, Shibata D, Sato F, Wang S, Olaru A, et al. Application of cDNA microarrays to generate a molecular taxonomy capable of distinguishing between colon cancer and normal colon. Oncogene 2002; 21:4855 - 62; http://dx.doi.org/10.1038/sj.onc.1205613; PMID: 12101425
   PubMed Web of Science ®Google Scholar
• Laiho P, Kokko A, Vanharanta S, Salovaara R, Sammalkorpi H, Järvinen H, Mecklin JP, Karttunen TJ, Tuppurainen K, Davalos V, et al. Serrated carcinomas form a subclass of colorectal cancer with distinct molecular basis. Oncogene 2007; 26:312 - 20; http://dx.doi.org/10.1038/sj.onc.1209778; PMID: 16819509
   PubMed Web of Science ®Google Scholar
• Tsuji S, Midorikawa Y, Takahashi T, Yagi K, Takayama T, Yoshida K, Sugiyama Y, Aburatani H. Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis. Br J Cancer 2012; 106:126 - 32; http://dx.doi.org/10.1038/bjc.2011.505; PMID: 22095227
   PubMed Web of Science ®Google Scholar
• Li R, Hu Z, Sun SY, Chen ZG, Owonikoko TK, Sica GL, Ramalingam SS, Curran WJ, Khuri FR, Deng X. Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer. Mol Cancer Ther 2013; 12:2200 - 12; http://dx.doi.org/10.1158/1535-7163.MCT-13-0095; PMID: 23894143
   PubMed Web of Science ®Google Scholar
• Benavente S, Huang S, Armstrong EA, Chi A, Hsu KT, Wheeler DL, Harari PM. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clin Cancer Res 2009; 15:1585 - 92; http://dx.doi.org/10.1158/1078-0432.CCR-08-2068; PMID: 19190133
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melisi D, De Vita F, De Placido S, Bianco AR, et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 2004; 10:784 - 93; http://dx.doi.org/10.1158/1078-0432.CCR-1100-03; PMID: 14760102
   PubMed Web of Science ®Google Scholar
• Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, Rinehart C, Seidel B, Yee D, Arteaga CL, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008; 118:2609 - 19; PMID: 18568074
   PubMed Web of Science ®Google Scholar
• Lu Y, Li X, Liang K, Luwor R, Siddik ZH, Mills GB, Mendelsohn J, Fan Z. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Res 2007; 67:8240 - 7; http://dx.doi.org/10.1158/0008-5472.CAN-07-0589; PMID: 17804738
   PubMed Web of Science ®Google Scholar
• Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, Kerbel RS. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001; 61:5090 - 101; PMID: 11431346
   PubMed Web of Science ®Google Scholar
• Wheeler DL, Iida M, Kruser TJ, Nechrebecki MM, Dunn EF, Armstrong EA, Huang S, Harari PM. Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Cancer Biol Ther 2009; 8:696 - 703; http://dx.doi.org/10.4161/cbt.8.8.7903; PMID: 19276677
   PubMed Web of Science ®Google Scholar
• Yamasaki F, Johansen MJ, Zhang D, Krishnamurthy S, Felix E, Bartholomeusz C, Aguilar RJ, Kurisu K, Mills GB, Hortobagyi GN, et al. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res 2007; 67:5779 - 88; http://dx.doi.org/10.1158/0008-5472.CAN-06-3020; PMID: 17575145
   PubMed Web of Science ®Google Scholar
• Zhang X, Guo A, Yu J, Possemato A, Chen Y, Zheng W, Polakiewicz RD, Kinzler KW, Vogelstein B, Velculescu VE, et al. Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T. Proc Natl Acad Sci U S A 2007; 104:4060 - 4; http://dx.doi.org/10.1073/pnas.0611665104; PMID: 17360477
   PubMed Web of Science ®Google Scholar
• Lui VW, Peyser ND, Ng PK, Hritz J, Zeng Y, Lu Y, Li H, Wang L, Gilbert BR, General IJ, et al. Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. Proc Natl Acad Sci U S A 2014; 111:1114 - 9; http://dx.doi.org/10.1073/pnas.1319551111; PMID: 24395800
   PubMed Web of Science ®Google Scholar
• Su F, Ren F, Rong Y, Wang Y, Geng Y, Wang Y, Feng M, Ju Y, Li Y, Zhao ZJ, et al. Protein tyrosine phosphatase Meg2 dephosphorylates signal transducer and activator of transcription 3 and suppresses tumor growth in breast cancer. Breast Cancer Res 2012; 14:R38; http://dx.doi.org/10.1186/bcr3134; PMID: 22394684
   PubMedGoogle Scholar
• Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen N, Tsurutani J, Dennis PA, Mills GB, Arteaga CL. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003; 22:2812 - 22; http://dx.doi.org/10.1038/sj.onc.1206388; PMID: 12743604
   PubMed Web of Science ®Google Scholar
• She QB, Solit D, Basso A, Moasser MM. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clin Cancer Res 2003; 9:4340 - 6; PMID: 14555504
   PubMed Web of Science ®Google Scholar
• Luwor RB, Baradaran B, Taylor LE, Iaria J, Nheu TV, Amiry N, Hovens CM, Wang B, Kaye AH, Zhu HJ. Targeting Stat3 and Smad7 to restore TGF-β cytostatic regulation of tumor cells in vitro and in vivo. Oncogene 2013; 32:2433 - 41; http://dx.doi.org/10.1038/onc.2012.260; PMID: 22751114
   PubMed Web of Science ®Google Scholar
• Wang Y, Robledo O, Kinzie E, Blanchard F, Richards C, Miyajima A, Baumann H. Receptor subunit-specific action of oncostatin M in hepatic cells and its modulation by leukemia inhibitory factor. J Biol Chem 2000; 275:25273 - 85; http://dx.doi.org/10.1074/jbc.M002296200; PMID: 10854424
   PubMed Web of Science ®Google Scholar
• Luwor RB, Wang B, Nheu TV, Iaria J, Tsantikos E, Hibbs ML, Sieber OM, Zhu HJ. New reagents for improved in vitro and in vivo examination of TGF-β signalling. Growth Factors 2011; 29:211 - 8; http://dx.doi.org/10.3109/08977194.2011.615311; PMID: 21913800
   PubMed Web of Science ®Google Scholar
• Luwor RB, Johns TG, Murone C, Huang HJ, Cavenee WK, Ritter G, Old LJ, Burgess AW, Scott AM. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res 2001; 61:5355 - 61; PMID: 11454674
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004; 6:1 - 6; PMID: 15068665
   PubMed Web of Science ®Google Scholar